CATALYST PHARMACEUTICALS, INC. 4

Chief Medical Officer William T. Andrews had all his Catalyst Pharmaceuticals common stock, options, and RSUs cashed out at the $31.50 per-share merger price in connection with the Angelini Pharma acquisition.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief Medical Officer William T. Andrews disposed of his equity awards in connection with the cash acquisition of the company by Angelini Pharma S.p.A. All 2,309 shares of common stock were effectively cashed out at the merger price of $31.50 per share (about $72.7K). In addition, options to purchase 124,447 shares at a $24.90 strike and 98,652 shares at a $22.77 strike were canceled and converted into cash payments equal to the per-share option spread versus the $31.50 merger price, implying gross option value of roughly $820K and $860K, respectively. Restricted stock units covering 12,209 shares (vested in full at closing) and a further 29,776 RSUs were also canceled for cash based on the $31.50 consideration (about $384K total). Following these merger-triggered cashouts of stock, options, and RSUs, Andrews no longer reported any equity ownership in Catalyst, as the issuer ceased to exist as a standalone public company post-transaction.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000171

Alert Tier

6